Tusamitamab ravtansine (SAR408701)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Tusamitamab ravtansine (SAR408701), covering 2024-12-05 to 2024-12-05. Get the full timeline:
Most recent: Clinical Trial Update: Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer [Phase 2]